

A new role for the P2Y-like GPR17 receptor in the modulation of multipotency of oligodendrocyte precursor cells *in vitro*

Marta Boccazzi¹, Davide Lecca¹, Davide Marangon¹, Fabio Guagnini², Maria P. Abbracchio^{1*}, Stefania Ceruti^{1*§} (* equally contributing)

¹Laboratory of Molecular and Cellular Pharmacology of Purinergic Transmission – Department of Pharmacological and Biomolecular Sciences – Università degli Studi di Milano – via Balzaretti, 9 – 20133 Milan (Italy)

²Previous affiliation: Sanofi Midy Research Center - Exploratory Unit Sanofi R&D - via G. Sbodio, 2 - 20100 Milan (Italy). Present affiliation: Allergy Therapeutics - via IV Novembre, 76 – 20019 Settimo Milanese (Milan) Italy

§Corresponding author:

Ceruti Stefania

Tel. +39-0250318261

Fax. +39-02-50318284

email: stefania.ceruti@unimi.it

Acknowledgements

Cangrelor was a kind gift of The Medicine Company, Parsippany, USA. Anti-SV2 and anti-Syt primary antibodies were a kind gift of Dr. C. Verderio (National Research Council, CNR, Milan). Anti-Ran2 antibody was a kind gift of Prof. Carla Taveggia (Axo-Glia Unit, Institute of Experimental Neurology Division of Neuroscience, San Raffaele Scientific Institute, Milan). Anti-GPR17 antibody for Western blotting analysis was produced and purified by Dr. Patrizia Rosa

(National Research Council, CNR, Milan), who also provided us OliNeu cells. Authors wish to thank Dr. Giulia Magni for her help with analysis of data. MB was previously supported by the fellowship “Dote Ricerca Applicata” by Sanofi-Aventis and Regione Lombardia. She is currently supported by a fellowship from the Fondazione Umberto Veronesi.

Abstract

Oligodendrocyte precursor cells (OPCs, also called NG2 cells) are scattered throughout brain parenchyma, where they function as a reservoir to replace lost or damaged oligodendrocytes, the myelin-forming cells. The hypothesis that, under some circumstances, OPCs can actually behave as multipotent cells, thus generating astrocytes and neurons as well, has arisen from some *in vitro* and *in vivo* evidence, but the molecular pathways controlling this alternative fate of OPCs are not fully understood. Their identification would open new opportunities for neuronal replace strategies, by fostering the intrinsic ability of the brain to regenerate. Here, we show that the anti-epileptic epigenetic modulator valproic acid (VPA) can promote the generation of new neurons from NG2⁺ OPCs under neurogenic protocols *in vitro*, through their initial de-differentiation to a stem cell-like phenotype that then evolves to “hybrid” cell population, showing OPC morphology but expressing the neuronal marker β III-tubulin and the GPR17 receptor, a key determinant in driving OPC transition towards myelinating oligodendrocytes. Under these conditions, the pharmacological blockade of the P2Y-like receptor GPR17 by cangrelor, a drug recently approved for human use, partially mimics the effects mediated by VPA thus accelerating cells’ neurogenic conversion. These data show a co-localization between neuronal markers and GPR17 *in vitro*, and suggest that, besides its involvement in oligodendrogenesis, GPR17 can drive the fate of neural precursor cells by instructing precursors towards the neuronal lineage. Being a membrane receptor, GPR17 represents an ideal “druggable” target to be exploited for innovative regenerative approaches to acute and chronic brain diseases.

Keywords

NG2 cells, GPR17, neurogenesis, valproic acid, oligodendrocyte precursor cells

Introduction

After embryonic development, quiescent neural stem-like progenitors (NPCs) still persist in two brain's neurogenic niches (i.e. the subventricular zone of the lateral ventricles and the subgranular layer of the hippocampus) and in central nervous system (CNS) parenchyma throughout life (reviewed in [1, 2]). Parenchymal NPCs include subsets of astrocytes, that, when activated, re-acquire stem/progenitor cells properties [3], and oligodendrocyte precursor cells (OPCs), also known as polydendrocytes, expressing the membrane chondroitin sulphate proteoglycan NG2 [1, 4]. NG2-positive cells have been originally identified as the progenitors of the myelin-forming cells of the brain and spinal cord (reviewed in [5]) that spontaneously differentiate to mature oligodendrocytes both *in vitro* and *in vivo* [6]. The hypothesis that OPCs can behave as multipotent progenitors was raised after the demonstration that NG2-cells purified from early postnatal rat optic nerves have the ability to revert to stem-like cells which eventually differentiate to oligodendrocytes, astrocytes and even neurons [7–9]. Afterwards, with the development of genetic labeling, transgenic mouse models, in particular those carrying the Cre-loxP technology, have become a useful tool for fate-mapping studies to investigate the multipotency of these cells *in vivo*. For example, following brain ischemia due to permanent middle cerebral artery occlusion (MCAo), generation of both astrocytic and neuronal precursors from NG2⁺ cells was observed in adult NG2creBAC:ZEG double transgenic mice, in which enhanced green fluorescent protein (EGFP) is expressed in OPCs and their progeny, thus allowing to visualize their final phenotype [10]. However, conflicting data arise from the different transgenic mouse models employed, and the controversy around the multipotency and neurogenic potential of OPCs *in vivo* is still an open issue [11–15].

Thus, knowledge of the mechanisms underlying the commitment of OPCs towards either myelinating oligodendrocytes or distinct neural lineage is mandatory, but still incomplete. In this respect, we have recently focused our attention on the possible role exerted by the P2Y-like receptor GPR17, which is closely related to both purinergic P2Y and CysLT receptors [16].

Notably, GPR17 is one of the three genes differentially expressed by human adult hippocampal precursor cells when compared to embryonic stem cells [17]. We and others have demonstrated that GPR17 is transiently expressed at specific differentiation stages of OPCs, undergoes a tightly regulated modulation to drive OPC maturation towards fully mature oligodendrocytes, and contributes to their reaction to harmful conditions [18–22].

However, while in the intact CNS GPR17 is almost exclusively expressed in OPCs, this receptor is rapidly induced in cells of the neuronal lineage inside and at the border of ischemic/traumatic lesions in both the MCAo model [16, 23] and in a rodent model of spinal cord injury [24]. Moreover, more recent data have shown that GPR17 regulates the proliferation of a population of doublecortin (DCX)⁺ neuronal progenitors (neuroblasts) in hippocampal dentate gyrus [25], to suggest that, besides its established role in oligodendrogenesis, GPR17 may also be involved in neuronal specification. On this basis, we raised the hypothesis that GPR17 could regulate the fate of NPCs addressing them to either the oligodendroglial or the neuronal lineages.

This work was specifically undertaken to elucidate the possible role of GPR17 in controlling the switch of OPCs towards a neurogenic fate. To this aim, we purposely set up two culturing protocols known to unveil the multipotency of OPCs *in vitro*, and we fostered neurogenesis by exposing cultures to the epigenetic anti-epileptic agent valproic acid (VPA), known to promote the generation of new neurons through inhibition of histone deacetylases in progenitor cells [26–28]. In the different experimental conditions, we analyzed the expression of GPR17 and the effect of its pharmacological manipulation on cell progeny. Results show, for the first time, the presence of GPR17 in a “hybrid” cell population that still bore an OPC morphology but already expressed neuronal markers; moreover, blockade of GPR17 by the P2Y antagonist Cangrelor, that also acts as an antagonist at GPR17 [16] partially reproduced VPA-mediated increase in neurogenesis, thus unveiling a new potential pharmacological approach to shift the cell fate of OPCs towards the generation of new neuron-like cells.

Materials and Methods

Primary OPC Cultures

OPCs were isolated from mixed glial cultures from postnatal day 2 Sprague-Dawley rat cortex, by the shaking method [22] followed by immunopurification [29]. This additional step consists of a negative selection procedure to remove undesired cells (e.g., astrocytes, meningeal cells and microglia/macrophages) by means of the Ran-2 antibody, which does not bind to OPCs [30].

A layer of anti-immunoglobulin antibodies (1 mg/ml anti-IgG, MP Biomedicals, Santa Ana, CA) was adsorbed to empty petri dishes the day before culture shaking and incubated overnight at 4°C, thereby improving the subsequent binding of cell-type specific antibody. The following day, mixed cultures were shaken on an orbital shaker for 3-4 hours at 200 rpm. In the meantime, IgG coated dishes were rinsed 3 times with PBS and incubated for at least 3 hours at room temperature (RT) with a solution containing RAN2 antibody (RAN2-Ab, kindly provided by Prof. Carla Taveggia, Axo-Glia Unit, Institute of Experimental Neurology Division of Neuroscience, San Raffaele Scientific Institute, Milan) and consisting in 0.5 mL RAN2-Ab + 6 mL of Minimum Essential Medium with Earle's salts and L-glutamine (MEM, Life Technologies) + 1 mg/ml Bovine Serum Albumin (BSA, Sigma-Aldrich) + 25 mM HEPES pH 7.5 (Sigma-Aldrich).

At the end of shaking, the medium containing the detached cells was collected from each flask in 50 ml sterile conical tubes and centrifuged for 10 min at 290 g. Pellets were resuspended in NM15 Medium containing MEM, 15% heat-inactivated fetal bovine serum (FBS, Euroclone), 6 mg/ml glucose (Sigma-Aldrich), and penicillin–streptomycin (100 U/ml and 100 µg/ml, respectively; Euroclone) + insulin (5 µg/ml; Sigma-Aldrich), and the cell suspension was incubated at RT in a first RAN2-Ab-precoated plate. After 20 min, floating cells were transferred to a second RAN2-Ab-precoated plate and incubated for additional 20 min at RT. The supernatant was then collected and centrifuged at 290 g for 10 min. The resulting pellet was resuspended in the appropriate medium according to the subsequent protocol (see below). Isolated OPCs were plated

onto poly-D,L-ornithine- (final concentration 5 µg/ml; Sigma-Aldrich) coated 13 mm diameter glass coverslips (15,000 cells/well) for immunocytochemistry or 35 mm diameter Petri dishes (100,000 cells/well) for Western blot analysis.

To verify whether OPCs can generate neurons under a standard protocol of oligodendrocyte differentiation [20, 21, 22], cells were plated in Neurobasal medium with 2% B27 Supplement (both from Life Technologies), 2 mM L-glutamine, 10 ng/mL human platelet-derived growth factor BB (PDGF-BB, Sigma-Aldrich), and 10 ng/mL human basic fibroblast growth factor (bFGF, R&D Systems) to promote proliferation. After 2 days OPCs were shifted to differentiating medium (i.e., Neurobasal medium lacking growth factors), and either grown under control conditions or exposed to the anticonvulsant agent valproic acid (VPA, 500 µM) for 24-72 hours, fixed and immunostained for GPR17 and the neuronal marker β III-tubulin (see below).

Neurogenic protocols

To test the ability of OPCs to generate neurons, we applied two published protocols claimed to foster OPC transition towards neuroblasts [7, 27].

A 3-phases protocol [7] was renamed here as neurogenic protocol #1 (Figure 1a). Cells were initially maintained for 5 days in DMEM Medium (consisting in DMEM high glucose supplemented with penicillin–streptomycin 100 U/ml and 100 µg/ml, respectively; 1 mM Sodium Pyruvate; 2.5 µg/mL Fungizone; 2 mM L-Glutamine; all purchased from Euroclone) +10 ng/ml PDGF-BB + B27 supplement (1:50) to induce OPCs proliferation (phase A). Cells were then shifted to DMEM Medium + 10 ng/ml PDGF-BB + B27 supplement (1:50) + 15% FBS to promote their de-differentiation towards type 2 astrocytes and cultured for 3 days (phase B). Finally, cells were maintained for 5 additional days in DMEM Medium + B27 supplement (1:50) +10 ng/ml basic fibroblast growth factor (bFGF, R&D) to induce their differentiation along the three neural lineages (phase C).

We then set up an additional neurogenic protocol, renamed here as neurogenic protocol #2 (Figure 1b; [27]). Cells were exposed for 2 days to Proliferation Medium (i.e., DMEM Medium + 10 ng/ml PDGF-BB + 10 ng/ml bFGF + B27 supplement (1:50); phase PM) and then committed to differentiate into oligodendrocytes by removing mitogens for 1 day (Differentiation Medium; phase DM). Finally, cells were cultured in Stem Cell Medium composed by DMEM/F-12 (Life Technologies), Glutamine (1 mM), Glucose (25 mM, Sigma-Aldrich) and B27 supplement (1:50) for 3 days (phase SCM), which directly redirect OPCs to the three neural lineages [27].

In both protocols, at the end of the different phases either cells were fixed with 4% paraformaldehyde and processed for immunocytochemistry or whole-cell lysates were prepared and analyzed by Western blotting (see Results and Figures).

Pharmacological treatments

In either neurogenic protocol, we have verified if and how the exposure to various pharmacological agents (including GPR17 receptor ligands) can modulate OPCs plasticity and their differentiation to neurons. In particular, we have utilized the non-selective GPR17 agonist UDP-glucose (UDP-glc; 100 μ M [16, 20–23, 31–34]) and antagonist Cangrelor (Cang; 10 μ M), in parallel to VPA (500 μ M). All reagents were obtained from Sigma-Aldrich, except for Cangrelor that was a kind gift of The Medicines Company (Parsippany, NJ, USA). In neurogenic protocol #1 cells were treated with the different pharmacological agents during phase C only, whereas in neurogenic protocol #2 cells were treated during both phase DM and SCM (see Figure 1a, b).

Immunocytochemistry, image processing and data analysis

Fixed cells were subjected to immunocytochemistry as previously described [20]. The following antibodies and final dilutions were used: primary antibodies: rabbit anti-GFAP (1:600, Dako Italia, Cernusco sul Naviglio, Milan, Italy), mouse anti- β III-tub (1:1,000; Promega, Milan, Italy), mouse anti-NG2 (1:200; Abcam, Cambridge, UK), and rabbit anti-GPR17 (1:100; Cayman

Chemical Company, Ann Arbor, MI); secondary antibodies: goat anti-rabbit or goat anti-mouse antibodies conjugated to AlexaFluor®488 or AlexaFluor®555 (all 1:600, 1 hour at RT; Life Technologies). Nuclei were then labeled with the fluorescent dye Hoechst-33258 (1:10,000 in PBS; Life Technologies) and coverslips were mounted in Dako Fluorescence Mounting Medium (Dako).

Cells were finally analyzed by a fluorescent microscope (Zeiss, Jena, Germany). In each coverslip, the total number of cells, evaluated by counting Hoechst-33258⁺ nuclei, and the number of GPR17-, β III-tubulin, GFAP- or NG2-positive cells were determined in 20 randomly chosen optical fields under a 40x magnification. The total number of cells counted for each experimental condition was between 300 and 500.

To evaluate the intensity of GPR17 staining in OPCs cultured in standard differentiating conditions, fluorescent images were captured under a Zeiss Axiovert 200M microscope (Carl Zeiss) equipped with a CCD camera module at 40x magnification. Densitometric analysis was performed after converting the fluorescent signals to gray-scale values. The mean gray value in 10 randomly chosen optical field/coverslip was measured by the ImageJ software.

Western-blotting analysis

Whole-cell lysates were prepared and analyzed by Western blotting as previously described [35]. Cell pellets were homogenized on ice in lysis buffer (20 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.5% sodium deoxycholate, 1% Triton, 0.1% SDS) added with 1:100 protease inhibitor cocktail (Sigma-Aldrich). Thirty μ g aliquots from each protein sample were loaded on 11% sodium-dodecylsulphate polyacrylamide gels, and blotted onto nitrocellulose or PVDF membranes (Bio-Rad Laboratories, Milan, Italy). Membranes were then saturated with 10% non-fat dry milk in Tris-buffered saline (TBS; 1 mM Tris-HCl, 15 mM NaCl, pH 8) for 1 hour at RT, and incubated overnight at 4°C with mouse anti-synaptic vesicle2 (SV2, 1:2,000) and anti- β III-tub (1:1,000, Promega, Milan, Italy) or rabbit anti-synaptotagmin (Syt, 1:2,000; anti-SV2 and anti-Syt are a kind gift of Dr. C. Verderio, CNR, Milan), anti-CNPase (1:250, Santa Cruz), and anti-GPR17 primary

antibodies (1:100; home-made polyclonal antibody from Dr. Patrizia Rosa, CNR, Milan) all in 5% non-fat dry milk in TBS. Membranes were then washed in TBS-T (TBS plus 0.1% Tween20[®]), incubated for 1 h with goat anti-rabbit or anti-mouse secondary antibodies conjugated to horseradish peroxidase (1:4,000 or 1:2,000, respectively in 5% non-fat dry milk in TBS; Sigma-Aldrich). Detection of proteins was performed by enhanced chemiluminescence (ECL, Amersham Biosciences, Milan, Italy) and autoradiography. Non-specific reactions were evaluated in the presence of the secondary antibodies alone.

Luciferase reporter assay

For the analysis of promoter induction, the Oli-neu murine cell line was cultured in Sato medium containing 1% horse serum). The day after seeding, cells were transfected with a reporter construct containing an active region of the human GPR17 promoter, as previously described [36]. Exposure to 1 mM VPA was started the following day and lasted 48 h. The Dual Luciferase Reporter Assay (Promega) was performed according to the manufacturer's instructions.

Statistical analysis

Data were analyzed using the GraphPad Prism5 software. Differences between experimental conditions were calculated using either unpaired two-tailed Student's t test, or one-way ANOVA followed by the Bonferroni's post-hoc test. A p value <0.05 was considered as significant.

Results

NG2⁺ OPCs are multipotent cells, and their multipotency is unveiled by specific neurogenic protocols.

When cultured in differentiating conditions, NG2⁺ OPCs progressively mature to myelinating oligodendrocytes [20–23]. To verify whether their intrinsic multipotency can be unveiled under these standard culturing conditions, we isolated rat OPCs from mixed cortical glial

cell cultures, grew them for 24-72 hours under control (CTR) conditions or in the presence of 500 μ M VPA (an antiepileptic agent known to stimulate neurogenesis by inhibiting histone deacetylases; [26–28]), and counted the number of β III-tubulin (β III-tub)⁺ cells.

Very few β III-tub⁺ cells were observed at any of the time points tested either in CTR cultures or following exposure to VPA (Figure 2a), with a trend to decrease with time in culture. When this cell population was evaluated as percentage of the total number of cells (Figure 2b), values between 0.60% and 0.35% were obtained (Figure 2c), thus suggesting that these culturing conditions are not able to switch OPCs from their oligodendrocyte fate to a neurogenic one, not even in the presence of a known pro-neurogenic agent like VPA. Thus, to unmask the latent ability of OPCs to generate neurons, we grew them according to two protocols, renamed here neurogenic protocol #1 [7] and neurogenic protocol #2 ([27]; see Materials and Methods and Figure 1). At the end of each phase we performed immunocytochemical analysis to characterize the composition of the cell population.

Concerning protocol #1, at the end of phase A the majority of cells were NG2⁺ OPCs, while only few GFAP⁺ astrocytes were observed (Figure 3; see histograms in a and representative picture in b). A significant population of cells expressed GPR17 (Figure 3a), with more than 60% of GPR17⁺ cells also coexpressing NG2, thus confirming that the receptor decorates a subpopulation of early OPCs (Figure 3b) in line with our already published results [20–22]. At the end of phase B, cells de-differentiated to multipotent and undifferentiated precursors characterized by strong GFAP immunoreactivity and branched morphology (Figure 3c). Moreover, expression of both NG2 and GPR17 was dramatically down regulated compared to phase A (Figure 3a). At the end of the last phase (phase C), that re-addresses GFAP⁺ undifferentiated precursors to all the three neural lineages, the majority of the cell population is represented by OPCs re-expressing NG2 and GPR17, whereas the number of GFAP⁺ cells was decreased compared to phase B (Figure 3a,b). Interestingly, we also observed a trend to increase in the number of β III-tub⁺ neuron-like cells (Figure 3e; example picture in d), thus demonstrating that neurogenic protocol #1 succeeded in

addressing a subpopulation of undifferentiated GFAP⁺ precursors towards a neuronal fate. In agreement with literature data, β III-tub⁺ neuron-like cells showing a bipolar shape (Figure 3d) never co-expressed either NG2 (see split fluorescence channels in Supplementary Figure 1) or GPR17 (see also below).

We next characterized the progeny of OPCs grown under neurogenic protocol #2 after one day in DM or three days in SCM (see Materials and Methods; Figure 1). Also this protocol was able to unveil the multipotency of OPCs and to redirect NG2⁺ cells also towards a neuronal fate, as demonstrated by a significant increase in the number of β III-tub⁺ neuron-like cells at the end of SCM phase compared to the end of phase DM (Figure 4a). In parallel, the number of NG2⁺ cells decreased significantly when cells were shifted to SCM suggesting that at least a fraction of these cells were re-addressed towards a different fate. The number of GPR17-expressing cells was instead similar at the end of both phases (Figure 4b), with the vast majority of the GPR17⁺ cells being NG2-expressing OPCs at the end of incubation in DM (Figure 4c), as expected.

Valproic acid implements the neurogenic potential of OPCs and modulates the expression of GPR17.

We then verified if and how exposure to VPA (500 μ M) and to purinergic receptor ligands targeting GPR17 could modulate OPC multipotency and their commitment towards neurons with either neurogenic protocol. We chose a GPR17 antagonist (Cang; 10 μ M), and a GPR17 agonist (UDP-glc; 100 μ M [16, 20–23, 31–34]). In neurogenic protocol #1 cells were treated with the different pharmacological agents during phase C only, whereas in neurogenic protocol #2 cells were treated during both phase DM and SCM (see Figure 1 and Materials and Methods for details).

Exposure to VPA led to a significant increase in the total number of β III-tub⁺ cells at the end of both neurogenic protocols, in parallel to a reduction in the number of GPR17⁺ cells (Figure 5a). No differences were instead observed between control and VPA-treated cells in the expression of the OPC marker NG2 (data not shown).

To further confirm the neuronal commitment of OPCs, we performed Western blot analysis on cell lysates from CTR and VPA-treated cultures at the end of phase C (neurogenic protocol #1; Figure 5b, left) or phase SCM (neurogenic protocol #2; Figure 5b, right). Increase in β III-tub and decrease in GPR17 expression were observed with either neurogenic protocol, thus fully confirming data from immunocytochemistry, and suggesting an attempt of OPCs to escape from their “classical” oligodendrocyte fate. In neurogenic protocol #2, we also investigated the expression of two neuronal synaptic proteins (namely, synaptic vesicles 2, SV2 and synaptotagmin, syt). VPA induced a marked increase in SV2 expression compared to control cells, whereas Syt expression was unaffected (Figure 5b, right). Taken together, our results confirm that VPA stimulates the differentiation of OPCs toward cells committed to neuronal differentiation, as suggested by the presence of synaptic vesicle proteins.

Interestingly, when primary rat OPCs were grown in standard differentiating conditions in the presence of VPA for 24 hours, we also observed a reduction of GPR17 expression compared to control cultures (Figure 5c), despite no changes in the generation of new neuron-like cells (see Figure 2). This suggested us that VPA could have a direct action on GPR17 promoter, which is independent from its pro-neurogenic activity. Thus, to verify whether VPA directly influences GPR17 expression, we transfected the immortalized murine oligodendroglial Olineu cell line with a reporter construct in which an active portion of the GPR17 promoter had been previously cloned. In this reporter assay, VPA showed an inhibitory effect on GPR17 promoter activity compared to the empty vector (Figure 5d). Overall, these data suggest that VPA can modify GPR17 expression in OPCs cells by directly acting on its promoter sequence.

Concerning the effects of the pharmacological modulation of GPR17, using neurogenic protocol #1, we observed a significant increase in the number of β III-tub⁺ cells after exposure to Cang (Figure 5e), whereas UDP-glc exerted no effect. Conversely, in neurogenic protocol #2 the number of β III-tub expressing cells seemed to be unaffected by either GPR17 ligand (Figure 5f).

Exposure to either Cang or UDP-glc did not modify the number of GPR17-expressing cells in both neurogenic protocol #1 (Figure 5e), and neurogenic protocol #2 (Figure 5f). Thus, under the culturing conditions of neurogenic protocol #1 blockade of GPR17 receptor facilitates the neurogenic progression of OPCs, whereas receptor activation with UDP-glc exerts no effect.

Exposure to Cangrelor or VPA increases the percentage of GPR17⁺ cells coexpressing β III-tubulin

Two morphologically distinct groups of β III-tub⁺ cells were observed at the end of both neurogenic protocols: the first showed a typical bipolar neuroblast shape probably representing immature neurons (see above; arrow in Figure 3d), whereas the second and more abundant type of cells still bore an OPC-like morphology (arrows in Figure 6). As already mentioned above, in agreement with literature data, the former cell population never expressed GPR17. Conversely, in the latter cell population, a fraction of β III-tub/GPR17 double-positive cells was detected already under CTR conditions at the end of phase C and of phase SCM (Figure 6a, b). This is particularly interesting since no colocalization of GPR17 with neuronal markers has ever been observed *in vitro*. The “hybrid” β III-tub/GPR17 double-positive cell population was not detected in the early phases of either neurogenic protocol, and may represent an intermediate precursor stage preceding the neuronal stage at which GPR17 is downregulated. Re-expression of GPR17 at this intermediate stage suggests that, in a subset of precursors and under specific neurogenic conditions, this receptor may contribute to drive precursors cells to a neuronal destiny.

On this premises, we analyzed the effects of the above-mentioned pro-neurogenic pharmacological treatments on the population of GPR17/ β III-tub double-positive cells under both neurogenic protocols. In neurogenic protocol #1, the percentage of GPR17/ β III-tub double-positive cells over the total cell population (evaluated by counting Hoechst-33258⁺ cell nuclei) was similar in control cultures or after exposure to UDP-glc (100 μ M; control: 3.10 \pm 1.29%, UDPglc: 2.76 \pm 0.89%; 20 optical fields from 3 coverslips/condition), whereas it increased in cultures treated

with either Cang (10 μ M; control: $2.39 \pm 0.62\%$, Cang: $4.92 \pm 1.00\%$; $p < 0.05$ unpaired two-tailed Student's t test; 20 optical fields from 3 coverslips/condition) or VPA (500 μ M; control: $2.39 \pm 0.62\%$, VPA: $5.38 \pm 1.24\%$; $p < 0.05$ unpaired two-tailed Student's t test; 20 optical fields from 3 coverslips/condition). An even more pronounced effect was observed when considering the percentage of GPR17/ β III-tub double-positive cells over the total number of GPR17⁺ cells, which in VPA- and Cang-treated cultures was three times and about twice as high as in CTR cultures, respectively. No changes were observed with UDP-glc (Figure 6a, c). With neurogenic protocol #2, at the end of phase SCM, a trend to increase in the percentage of GPR17/ β III-tub double-positive cells over the total number of GPR17⁺ cells was observed after exposure to VPA (Figure 6b, d).

Conversely, if the population of GPR17/ β III-tub double-positive cells is expressed as % of the total number of β III-tub⁺ cells, no changes were observed upon the various pharmacological treatments (Figure 6e, f). This further confirms that the observed effects are related to an action on GPR17, since either pharmacological treatment have no effect on the 60-70% of β III-tub⁺ cells that do not express the receptor.

Upon exposure to either VPA or Cang we also observed a trend to a decrease in the percentage of NG2/GPR17 double-positive cells calculated on the total number of cells (CTR: $23.28 \pm 10.85\%$, VPA: 8.73 ± 2.11 and Cang: $8.49 \pm 2.92\%$, 20 optical fields from 3 coverslips/condition), thus confirming that a subset of OPCs is shifting its fate from oligodendrocytes to neurons. Nevertheless, GPR17/NG2 double-positive cells still represented the majority of the GPR17⁺ cell population (control: $58.56 \pm 15.75\%$, VPA: 45.62 ± 8.40 , Cang: $55.10 \pm 18.33\%$, 20 optical fields from 3 coverslips/condition).

Taken together our results suggest that VPA and, to a lesser extent Cang, are able to select a population of “hybrid” cells with an OPC morphology that starts acquiring neuronal markers and expresses GPR17.

Discussion

The main results of the present paper are: (i) under specific neurogenic conditions *in vitro*, the transition from OPCs to cells of the three neural lineages is accompanied by appearance of an “hybrid” cell population, showing typical OPC morphology but expressing the neuronal marker β III-tub; (ii) interestingly, this new cell population also co-expresses GPR17, already known to stimulate OPC differentiation towards fully myelinating oligodendrocytes; (iii) exposure of de-differentiated precursors to Cangr, a GPR17 antagonist, partially mimics the effects mediated by the anti-epileptic epigenetic agent VPA and accelerates cells’ neurogenic conversion. These data show for the first time a co-localization between neuronal markers and GPR17 *in vitro*. Moreover, they extend the role of GPR17 in driving the fate of neural precursor cells, suggesting that, besides its involvement in oligodendrogenesis, this receptor may also instruct precursors to the neuronal lineage.

***In vitro* generation of β III-tub⁺ cells from NG2⁺ OPCs.**

Our initial experiments demonstrate that a very low percentage of β III-tub⁺ cells is detected when OPCs are cultured in standard conditions, which are known to promote their maturation towards myelinating oligodendrocytes [20–23], even in the presence of the neurogenic agent VPA (Figure 2; see also below). Besides, the trend to a reduction of their number over time in culture suggests that these cells could represent contaminating neurons surviving from the original mixed glial cell cultures.

Thus, we cultured NG2⁺ OPCs according to a 3-phase protocol, renamed here neurogenic protocol #1 [7], leading to their initial regression to an intermediate multipotent stage characterized by massive expression of GFAP (phase B) with no NG2 staining, which was then followed by GFAP downregulation, re-appearance of NG2 and, most important, acquisition of the typical neuronal marker β III-tub (phase C; Figure 3). Interestingly, these phenotypic shifts were accompanied by significant changes of GPR17 expression, which was, as expected, highly expressed in NG2⁺ cells but disappeared in the intermediate de-differentiated GFAP⁺ cells (Figure

3). This is in line with our previous *in vivo* and *in vitro* observations showing no colocalization of GPR17 with astrocytic markers [16, 23, 24], and demonstrating that GPR17 specifically decorates a subpopulation of early NG2⁺ OPCs [20–22, 24]. A similar pattern of GPR17 co-localization with NG2 (Figure 4) was observed with neurogenic protocol #2, which lacks the intermediate stage of cell de-differentiation to GFAP⁺ precursors, but unveils OPC multipotency thanks to the exposure to a defined SCM known to support stem cell growth ([27, 37]; Figure 1)

At the end of both protocols, the increased expression of the neuronal marker β III-tub confirms that multipotency *in vitro* is an intrinsic feature of a subpopulation of NG2⁺ OPCs. These results emphasize the notion that postnatal OPCs can no longer be considered as mere progenitors restricted to an oligodendroglial fate [38], but are indeed stem-like cells that can unveil their multipotency under specific conditions. This is also confirmed by the *in vivo* demonstration that, upon injury, adult parenchymal OPCs are reverted to an immature phenotype that more closely resembles that of neonatal OPCs [39].

Valproic acid fosters the neuronal commitment of OPCs and modulates GPR17 expression.

As already shown in literature [40], our data show that the above-mentioned neurogenic shift is markedly implemented by exposure to VPA (500 μ M), an anti-epileptic drug known to act as HDAC inhibitor ([41]; Figure 4). In particular, VPA increased the expression of the neuronal marker β III-tub, in parallel with an higher expression of synaptic vesicle protein 2 (SV2), an integral membrane protein expressed in synaptic vesicles [42, 43], suggesting commitment of OPCs towards neuroblasts that are acquiring proteins typically involved in synaptic transmission.

VPA treatment itself is not enough to induce OPCs to express β III-tub under standard differentiating conditions (Figure 2), but, nevertheless, VPA significantly reduced GPR17 expression even under these conditions (Figure 5c), suggesting a direct effect of the drug on GPR17 expression. This effect is more evident when VPA is added to either neurogenic protocol (Figure 5a, b), in line with the notion that inhibition of HDACs reduces the expression of genes driving

oligodendrocyte specification [26–28]. Our reporter assay (Figure 5d) also suggests that VPA inhibits GPR17 expression by likely regulating transcription factors that activate the GPR17 promoter, such as Olig1 or FoxO1 [18, 23, 44, 45], thus disrupting the balance between oligodendroglial commitment and stemcellness.

Despite being mostly expressed by NG2⁺ cells, under neurogenic culturing conditions GPR17 was surprisingly expressed by a subset of β III-tub⁺ cells whose number was increased by exposure to VPA up to more than 25% of the total number of GPR17-expressing cells (Figure 6). This cell population showed the typical highly branched morphology of OPCs, thus probably representing a sort of “hybrid” of differentiation that is intermediate between the oligodendrocyte and neuronal fates. Thus, besides being a trigger for oligodendroglial differentiation [21], the P2Y-like receptor GPR17 may also be involved in the neurogenic specification of OPCs. This was already suggested by previous findings [46] that highlighted a role for GPR17 in the neuronal differentiation of PC12 cells, via modulation of the effects induced by classical growth factors. It is worth mentioning that GPR17 expression was not observed on β III-tub⁺ cells displaying typical neuroblast morphology (see arrow in Figure 3D), suggesting that GPR17 expression in these precursors is transient and that the receptor is downregulated at later stages of neuronal differentiation. It may well be that GPR17 participates to neuronal specification during development, is turned down during adulthood, and is then re-activated under disease conditions, when endogenous reparative neurogenesis is switched on, as suggested by increased neuronal expression of GPR17 in the ischemic rat and mouse brain [16, 23], as well as in the injured spinal cord after a mechanical insult [24]. Alternatively, despite not being normally expressed in adult neurons, GPR17 may be involved in the formation of new neuronal cells in some specific brain areas where neurogenesis is preserved throughout adulthood, such as, for example, the hippocampus during learning and memory processes. In this respect, we have recently shown that GPR17 regulates the proliferation of a subpopulation of hippocampal doublecortin (DCX)⁺ neuronal progenitors involved in cognitive performances ([25]; see also below).

It has already been demonstrated that the systemic administration of VPA in rodents is associated with a reduction of oligodendrocyte generation and a corresponding increase of astrocytes and neurons [27]. Moreover, having been utilized in clinics as anti-epileptic [47], anti-migraine [48] and anti-maniac drug [49] for years, VPA profile in patients is rather well known, which could accelerate the translation of data to humans also for its use in other brain diseases. However, these very exciting perspectives must be confronted with the potential drawbacks linked to the high number of genes regulated through VPA-mediated mechanism [41].

Antagonism of GPR17 promotes the neurogenic transition of NG2⁺ precursors.

Our current data show that increased neurogenesis was also observed by exposing cultures to the Cang, acting as a GPR17 antagonist, whereas no changes were detected with UDP-glc (Figures 5, 6). Experiments were characterized by high variability, which is possibly linked to the use of heterogeneous primary cultures that are composed of non-synchronized cells at different stages of differentiation, and characterized by a different rate of proliferation, and by the application of complex, multistep neurogenic protocols. Thus, while the effect of VPA is very consistent due to its broad epigenetic mechanism, the variability observed upon GPR17 blockade can be explained with the transient expression of this membrane receptor during the whole differentiation program [19–22]. On the other hand, to explain the lack of significant effects by UDP-glc, cultured cells may themselves release endogenous GPR17 agonists that tonically regulate this receptor *in vitro*, thus making it difficult to unveil the effects mediated by exogenously-added compounds. Nevertheless, the present data showing implementation of the neurogenic fate by Cang are in strong agreement with our previous data on hippocampal GPR17 expressing DCX precursors, where receptor blockade with another antagonist, montelukast [16, 23] markedly increased the number of new mature neurons in parallel with increased animals' cognitive abilities [25].

In the present study, the more interesting and consistent results have been obtained with neurogenic protocol #1. This is possibly due to the fact that, at variance from protocol #2, this

protocol involves the de-differentiation of NG2⁺ progenitors to GFAP⁺ multipotent cells (phase B), which are likely more prone to undergo epigenetic and pharmacological modulation towards a neuronal progeny. Nevertheless, the overall major length of protocol #1 compared to protocol #2 (13 vs. 6 days, respectively) poses technical problems for future experiments aimed at further fostering neurogenesis by prolonging cell exposure to either VPA or Cang. At the end of protocol #1, in fact, cells start showing signs of suffering and death (not shown) due to the length of time in culture. However, these results build up the background for further analysis, for the set-up of pharmacological/biotechnological approaches preventing excessive tissue degeneration while enhancing local reparative mechanisms. Importantly, GPR17 is a membrane receptor, thus amenable for activation/blockade by signals present in the local CNS milieu and for exogenous regulation by drugs, at variance from protocols based on genetic manipulations which are less prone to clinical exploitation, due to important drawbacks, such as the potential to cause tumor growth and gene mutations. In this respect, the pharmacological manipulation of endogenous cells still represents a safer and useful strategy for possible clinical applications. It is worth mentioning that the *in vivo* treatment of ischemic animals with Cang markedly prevented brain damage evolution [16, 23], suggesting a protective role against injury development. However, Cangr acts also as a potent antagonist at the P2Y₁₂ receptor subtype which has been shown to be highly expressed in the megakaryocyte/platelet lineage [50]. In this respect, FDA has recently approved it (June 2015) as an antiplatelet agent for intravenous application. The present findings unveiling the neurogenic properties of Cangr are particularly interesting in view of strategies aimed at repurposing this drug for additional neuroprotective uses that could be envisaged to speed up the development of urgently needed medicines for these patients.

Overall, based on the well-known role of purinergic signaling in regulating the synchronized proliferation, migration, differentiation and death of embryonic and adult NPCs [51-54], our present results strengthen the evidence that the purinergic system crucially regulates neuronal progenitors also in brain parenchyma, outside the well-known neurogenic niches. The

pharmacological modulation of the purinergic system could therefore represent a promising and innovative approach to exploit the intrinsic ability of the adult brain to regenerate in acute and chronic neurodegenerative disorders.

Compliance with Ethical Standards

The Authors declare no conflicts of interest.

All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted. The study has been approved by the Council of the Department of Pharmacological and Biomolecular Sciences of the Università degli Studi di Milano (Milan, Italy). Experiments have been performed in accordance with National and European regulations regarding the protection of animals used for experimental and other scientific purposes (D.L. 26_2014; 2010/63/UE), as well as following the Society for Neuroscience's policies on the Use of Animals and Humans in Neuroscience Research.

References

1. Boda E, Buffo A (2010) Glial cells in non-germinal territories: insights into their stem/progenitor properties in the intact and injured nervous tissue. *Arch Ital Biol* 148:119–136.
2. Ming G, Song H (2011) Adult neurogenesis in the mammalian brain: significant answers and significant questions. *Neuron* 70:687–702. doi: 10.1016/j.neuron.2011.05.001
3. Buffo A, Rite I, Tripathi P, Lepier A, Colak D, Horn AP, Mori T, Gotz M (2008) Origin and progeny of reactive gliosis: A source of multipotent cells in the injured brain. *Proc Natl Acad Sci* 105:3581–3586. doi: 10.1073/pnas.0709002105
4. Nishiyama A, Komitova M, Suzuki R, Zhu X (2009) Polydendrocytes (NG2 cells): multifunctional cells with lineage plasticity. *Nat Rev Neurosci* 10:9–22. doi: 10.1038/nrn2495
5. Dimou L, Gallo V (2015) NG2-glia and their functions in the central nervous system. *Glia* 63:1429–1451. doi: 10.1002/glia.22859
6. Zhu X, Bergles DE, Nishiyama A (2008) NG2 cells generate both oligodendrocytes and gray matter astrocytes. *Dev Cambridge Engl* 135:145–157. doi: 10.1242/dev.004895
7. Kondo T, Raff M (2000) Oligodendrocyte precursor cells reprogrammed to become multipotential CNS stem cells. *Science* 289:1754–1757. doi: 10.1126/science.289.5485.1754
8. Kondo T, Raff M (2000) Basic helix-loop-helix proteins and the timing of oligodendrocyte differentiation. *Dev Cambridge Engl* 127:2989–2998.
9. Kondo T, Raff M (2004) Chromatin remodelling and histone modification in the conversion of oligodendrocyte precursors to neural stem cells. *Genes Dev* 18:2963–2972. doi: 10.1101/gad.309404

10. Honsa P, Pivonkova H, Dzamba D, Filipova M, Anderova M (2012) Polydendrocytes display large lineage plasticity following focal cerebral ischemia. *PLoS One* 7:e36816. doi: 10.1371/journal.pone.0036816
11. Rivers LE, Young KM, Rizzi M, Jamen F, Psachoulia K, Wade A, Kessaris N, Richardson WD (2008) PDGFRA/NG2 glia generate myelinating oligodendrocytes and piriform projection neurons in adult mice. *Nat Neurosci* 11:1392–1401. doi: 10.1038/nn.2220
12. Guo F, Maeda Y, Ma J, Xu J, Horiuchi M, Miers L, Vaccarino F, Pleasure D (2010) Pyramidal neurons are generated from oligodendroglial progenitor cells in adult piriform cortex. *J Neurosci* 30:12036–12049. doi: 10.1523/JNEUROSCI.1360-10.2010
13. Kang SH, Fukaya M, Yang JK, Rothstein JD, Bergles DE (2010) NG2+ CNS glial progenitors remain committed to the oligodendrocyte lineage in postnatal life and following neurodegeneration. *Neuron* 68:668–681. doi: 10.1016/j.neuron.2010.09.009
14. Dimou L, Simon C, Kirchhoff F, Takebayashi H, Götz M (2008) Progeny of Olig2-expressing progenitors in the gray and white matter of the adult mouse cerebral cortex. *J Neurosci* 28:10434–10442. doi: 10.1523/JNEUROSCI.2831-08.2008
15. Huang W, Zhao N, Bai X, Karram K, Trotter J, Goebbels S, Scheller A, Kirchhoff F (2014) Novel NG2-CreERT2 knock-in mice demonstrate heterogeneous differentiation potential of NG2 glia during development. *Glia* 62:896–913. doi: 10.1002/glia.22648
16. Ciana P, Fumagalli M, Trincavelli ML, Verderio C, Rosa P, Lecca D, Ferrario S, Parravicini C, Capra V, Gelosa P, Guerrini U, Belcredito S, Cimino M, Sironi L, Tremoli E, Rovati GE, Martini C, Abbracchio MP (2006) The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. *EMBO J* 25:4615–4627. doi: 10.1038/sj.emboj.7601341
17. Maisel M, Herr A, Milosevic J, Hermann A, Habisch HJ, Schwarz S, Kirsch M, Antoniadis G, Brenner R, Hallmeyer-Elgner S, Lerche H, Schwarz J, Storch A (2007) Transcription

- profiling of adult and fetal human neuroprogenitors identifies divergent paths to maintain the neuroprogenitor cell state. *Stem Cells* 25:1231–1240. doi: 10.1634/stemcells.2006-0617
18. Chen Y, Wu H, Wang S, Koito H, Li J, Ye F, Hoang J, Escobar SS, Gow A, Arnett HA, Trapp BD, Karandikar NJ, Hsieh J, Lu QR (2009) The oligodendrocyte-specific G protein-coupled receptor GPR17 is a cell-intrinsic timer of myelination. *Nat Neurosci* 12:1398–1406. doi: 10.1038/nn.2410
 19. Boda E, Viganò F, Rosa P, Fumagalli M, Labat-Gest V, Tempia F, Abbracchio MP, Dimou L, Buffo A (2011) The GPR17 receptor in NG2 expressing cells: focus on in vivo cell maturation and participation in acute trauma and chronic damage. *Glia* 59:1958–1973. doi: 10.1002/glia.21237
 20. Ceruti S, Viganò F, Boda E, Ferrario S, Magni G, Boccazzi M, Rosa P, Buffo A, Abbracchio MP (2011) Expression of the new P2Y-like receptor GPR17 during oligodendrocyte precursor cell maturation regulates sensitivity to ATP-induced death. *Glia* 59:363–378. doi: 10.1002/glia.21107
 21. Fumagalli M, Daniele S, Lecca D, Lee PR, Parravicini C, Fields RD, Rosa P, Antonucci F, Verderio C, Trincavelli ML, Bramanti P, Martini C, Abbracchio MP (2011) Phenotypic changes, signaling pathway, and functional correlates of GPR17-expressing neural precursor cells during oligodendrocyte differentiation. *J Biol Chem* 286:10593–10604. doi: 10.1074/jbc.M110.162867
 22. Fumagalli M, Bonfanti E, Daniele S, Zappelli E, Lecca D, Martini C, Trincavelli ML, Abbracchio MP (2015) The ubiquitin ligase Mdm2 controls oligodendrocyte maturation by intertwining mTOR with G protein-coupled receptor kinase 2 in the regulation of GPR17 receptor desensitization. *Glia* 63:2327–2339. doi: 10.1002/glia.22896
 23. Lecca D, Trincavelli ML, Gelosa P, Sironi L, Ciana P, Fumagalli M, Villa G, Verderio C, Grumelli C, Guerrini U, Tremoli E, Rosa P, Cuboni S, Martini C, Buffo A, Cimino M, Abbracchio MP (2008) The recently identified P2Y-like receptor GPR17 is a sensor of brain

- damage and a new target for brain repair. *PLoS One* 3:e3579. doi: 10.1371/journal.pone.0003579
24. Ceruti S, Villa G, Genovese T, Mazzon E, Longhi R, Rosa P, Bramanti P, Cuzzocrea S, Abbraccio MP (2009) The P2Y-like receptor GPR17 as a sensor of damage and a new potential target in spinal cord injury. *Brain* 132:2206–2218. doi: 10.1093/brain/awp147
 25. Marschallinger J, Schäffner I, Klein B, Gelfert R, Rivera FJ, Illes S, Grassner L, Janssen M, Rotheneichner P, Schmuckermair C, Coras R, Boccazzi M, Chishty M, Lagler FB, Renic M, Bauer H, Singewald N, Blümcke I, Bogdahn U, Couillard-Despres S, Lie DC, Abbraccio MP, Aigner L (2015) Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug. *Nat Commun* 6:8466. doi: 10.1038/ncomms9466
 26. Hsieh J, Nakashima K, Kuwabara T, Mejia E, Gage FH (2004) Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. *Proc Natl Acad Sci* 101:16659–16664. doi: 10.1073/pnas.0407643101
 27. Liu A, Han YR, Li J, Sun D, Ouyang M, Plummer MR, Casaccia-Bonnel P (2007) The glial or neuronal fate choice of oligodendrocyte progenitors is modulated by their ability to acquire an epigenetic memory. *J Neurosci* 27:7339–7343. doi: 10.1523/JNEUROSCI.1226-07.2007
 28. Shen S, Li J, Casaccia-Bonnel P (2005) Histone modifications affect timing of oligodendrocyte progenitor differentiation in the developing rat brain. *J Cell Biol* 169:577–589. doi: 10.1083/jcb.200412101
 29. Mayer-Pröschel M (2001) Isolation and Generation of Oligodendrocytes by Immunopanning. In: *Curr. Protoc. Neurosci.* John Wiley & Sons, Inc., Hoboken, NJ, USA, p Unit 3.13
 30. Bartlett PF, Noble MD, Pruss RM, Raff MC, Rattray S, Williams CA (1981) Rat neural antigen-2 (RAN-2): a cell surface antigen on astrocytes, ependymal cells, Müller cells and lepto-meninges defined by a monoclonal antibody. *Brain Res* 204:339–351.

31. Benned-Jensen T, Rosenkilde MM (2010) Distinct expression and ligand-binding profiles of two constitutively active GPR17 splice variants. *Br J Pharmacol* 159:1092–1105. doi: 10.1111/j.1476-5381.2009.00633.x
32. Buccioni M, Marucci G, Dal Ben D, Giacobbe D, Lambertucci C, Soverchia L, Thomas A, Volpini R, Cristalli G (2011) Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17. *Purinergic Signal* 7:463–468. doi: 10.1007/s11302-011-9245-8
33. Li WJ, Mao FX, Chen HJ, Qian LH, Buzby JS (2015) Treatment with UDP-glucose, GDNF, and memantine promotes SVZ and white matter self-repair by endogenous glial progenitor cells in neonatal rats with ischemic PVL. *Neuroscience* 284:444–458. doi: <http://dx.doi.org/10.1016/j.neuroscience.2014.10.012>
34. Dougherty JD, Fomchenko EI, Akuffo AA, Schmidt E, Helmy KY, Bazzoli E, Brennan CW, Holland EC, Milosevic A (2012) Candidate pathways for promoting differentiation or quiescence of oligodendrocyte progenitor-like cells in glioma. *Cancer Res* 72:4856–4868. doi: 10.1158/0008-5472.CAN-11-2632
35. Bianco F, Fumagalli M, Pravettoni E, D'Ambrosi N, Volonte C, Matteoli M, Abbracchio MP, Verderio C (2005) Pathophysiological roles of extracellular nucleotides in glial cells: differential expression of purinergic receptors in resting and activated microglia. *Brain Res Rev* 48:144–156. doi: 10.1016/j.brainresrev.2004.12.004
36. Fratangeli A, Parmigiani E, Fumagalli M, Lecca D, Benfante R, Passafaro M, Buffo A, Abbracchio MP, Rosa P (2013) The regulated expression, intracellular trafficking, and membrane recycling of the P2Y-like receptor GPR17 in Oli-neu oligodendroglial cells. *J Biol Chem* 288:5241–5256. doi: 10.1074/jbc.M112.404996
37. Belachew S (2003) Postnatal NG2 proteoglycan-expressing progenitor cells are intrinsically multipotent and generate functional neurons. *J Cell Biol* 161:169–186. doi: 10.1083/jcb.200210110

38. Dawson MR, Levine JM, Reynolds R (2000) NG2-expressing cells in the central nervous system: are they oligodendroglial progenitors? *J Neurosci Res* 61:471–479.
39. Moyon S, Dubessy AL, Aigrot MS, Trotter M, Huang JK, Dauphinot L, Potier MC, Kerninon C, Melik Parsadaniantz S, Franklin RJ, Lubetzki C (2015) Demyelination causes adult CNS progenitors to revert to an immature state and express immune cues that support their migration. *J Neurosci* 35:4–20. doi: 10.1523/JNEUROSCI.0849-14.2015
40. Liu J, Casaccia-Bonnel P (2010) Epigenetic regulation of oligodendrocyte identity. *Trends Neurosci* 33:193–201. doi: 10.1016/j.tins.2010.01.007
41. Monti B, Polazzi E, Contestabile A (2009) Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. *Curr Mol Pharmacol* 2:95–109.
42. Crèvecoeur J, Foerch P, Doupagne M, Thielen C, Vandenplas C, Moonen G, Deprez M, Rogister B (2013) Expression of SV2 isoforms during rodent brain development. *BMC Neurosci* 14:87. doi: 10.1186/1471-2202-14-87
43. Portela-Gomes GM, Lukinius A, Grimelius L (2000) Synaptic vesicle protein 2, a new neuroendocrine cell marker. *Am J Pathol* 157:1299–1309. doi: 10.1016/S0002-9440(10)64645-7
44. Ren H, Orozco IJ, Su Y, Suyama S, Gutiérrez-Juárez R, Horvath TL, Wardlaw SL, Plum L, Arancio O, Accili D (2012) FoxO1 target Gpr17 activates AgRP neurons to regulate food intake. *Cell* 149:1314–1326. doi: 10.1016/j.cell.2012.04.032
45. Wu JB, Shih JC (2011) Valproic acid induces monoamine oxidase A via Akt/forkhead box O1 activation. *Mol Pharmacol* 80:714–723. doi: 10.1124/mol.111.072744
46. Daniele S, Lecca D, Trincavelli ML, Ciampi O, Abbracchio MP, Martini C (2010) Regulation of PC12 cell survival and differentiation by the new P2Y-like receptor GPR17. *Cell Signal* 22:697–706. doi: 10.1016/j.cellsig.2009.12.006
47. Löscher W (2002) Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. *CNS Drugs* 16:669–694.

48. Hering R, Kuritzky A (1989) Sodium valproate in the treatment of cluster headache: an open clinical trial. *Cephalalgia* 9:195–198.
49. Pope HG, McElroy SL, Keck PE, Hudson JI (1991) Valproate in the treatment of acute mania. A placebo-controlled study. *Arch Gen Psychiatry* 48:62–68.
50. Burnstock G, Knight GE (2004) Cellular Distribution and Functions of P2 Receptor Subtypes in Different Systems. *Int Rev Cytol* 240:31–304.
51. Neary JT, Zimmermann H (2009) Trophic functions of nucleotides in the central nervous system. *Trends Neurosci* 32:189–198. doi: 10.1016/j.tins.2009.01.002
52. Ulrich H, Abbracchio MP, Burnstock G (2012) Extrinsic purinergic regulation of neural stem/progenitor cells: implications for CNS development and repair. *Stem Cell Rev* 8:755–767. doi: 10.1007/s12015-012-9372-9
53. Cavaliere F, Donno C, D'Ambrosi N (2015) Purinergic signaling: a common pathway for neural and mesenchymal stem cell maintenance and differentiation. *Front Cell Neurosci* 9:211. doi: 10.3389/fncel.2015.00211
54. Boccazzi M, Rolando C, Abbracchio MP, Buffo A, Ceruti S (2014) Purines regulate adult brain subventricular zone cell functions: contribution of reactive astrocytes. *Glia* 62:428–439. doi: 10.1002/glia.22614

Figure legends

Fig. 1

Schematic representation of the two neurogenic protocols utilized in this study (see text for details and drug concentrations). In neurogenic protocol #1 (a; [7]), pharmacological treatments were performed during phase C, whereas in neurogenic protocol #2 (b; [27]) exposure to the selected drugs was started at the beginning of phase DM up to the end of the experimental protocol. PM: proliferation medium; DM: differentiation medium; SCM: stem cell medium; VPA: valproic acid; Cang: Cangrelor; UDP-glc; UDP-glucose

Fig. 2

VPA does not promote the generation of β III-tubulin⁺ neurons from OPCs grown in standard differentiating conditions. (a, b, c) Histograms showing the number of β III-tubulin⁺ cells (a), the total number of cells (as evaluated by counting Hoechst33258-stained nuclei; b), and the percentage of β III-tubulin⁺ cells over the total cell population (c) in OPC cultures grown under standard differentiating conditions for 1-3 days. Cultures have been grown either under control condition (CTR) or exposed to 500 μ M VPA. Results are the mean of 3 coverslips/condition from 1 representative experiment. * $p < 0.05$ compared to CTR, unpaired two-tailed Students' t test

Fig. 3

Generation of β III-tubulin⁺ cells by exposing NG2⁺ OPCs to neurogenic protocol #1. (a) Histograms showing the number of cells expressing the cell markers NG2, GFAP, and GPR17 at the end of the three phases of neurogenic protocol #1 (data are the mean of 3-10 coverslips from 2-5 independent experiments; §§ $p < 0.01$ compared to phase A; ** $p < 0.01$ compared to phase B; One-way ANOVA Bonferroni post hoc test). (b) Pie charts showing the percentage of NG2-GPR17 double-positive cells over the total number of GPR17⁺ cells at the end of phases A and C. Data are the mean of 4-7 coverslips from 2-3 independent experiments. A representative image showing the

co-localization of GPR17 (green) and NG2 (red) at the end of phase A is shown on the right. Scale bar: 100 μ m. (c, d) Representative images of the progeny of NG2+ cells at the end of phases B and C. Arrow in d indicates a typical β III-tubulin+ (β III-tub) neuroblast, which does not co-express NG2 (see split fluorescence channels in Supplementary Fig. 1). Scale bars: 100 μ m. e) The graph shows the percentage of β III-tub+ cells at the end of each phase of neurogenic protocol #1

Fig. 4

In neurogenic protocol #2, incubation in stem cell medium (SCM) “per se” stimulates the generation of β III-tubulin+ cells. (a, b) Histograms showing the percentage of β III-tubulin+ (β III-tub; a) or GPR17+ and NG2+ (b) cells at the end of phase DM or phase SCM (see Figure 1b; * p <0.05, and ** p <0.01 unpaired two-tailed Student's t test, data are the mean of 3-10 coverslips from 2-4 independent experiments). (c) Pie chart showing the percentage of GPR17+ cells co-expressing NG2 over the total population of GPR17+ cells at the end of phase DM. Data are the mean of 7 coverslips from 4 independent experiments

Fig. 5

In both neurogenic protocols, exposure to VPA fosters the generation of β III-tubulin+ neurons, in parallel with a decreased expression of GPR17. (a) Histograms showing the effect of the treatment with VPA on the percentage of GPR17 and β III-tub+ cells at the end of the two neurogenic protocols. Data are the mean of 12-20 coverslips from 5-10 independent experiments. * p <0.05, ** p <0.01 unpaired two-tailed Student's t-test. (b) Western blotting analysis of the expression of the neuronal proteins β III-tub, synaptic vesicles 2 (SV2), and synaptotagmin (syt), of GPR17 and of the mature oligodendrocyte marker CNPase in cell cultures grown under control (CTR) condition or after VPA treatment in neurogenic protocol #1 (left) or #2 (right). β -actin is shown as internal loading control. One representative experiment out of 3 is shown. (c) Representative images of GPR17 expression in OPC cultures grown in standard differentiating medium under control

condition (CTR) or after a 24-hour treatment with VPA. Scale bars: 100 μ m. Histograms show the quantification of GPR17 expression measured as integrated density and expressed as arbitrary unit. Data are the mean of 3 coverslips/condition from 1 representative experiment, and are shown as mean percentage \pm SEM of CTR values set to 100%. * $p < 0.05$ compared to CTR, unpaired two-tailed Students' t test. (d) Effect of VPA treatment on GPR17 promoter activity in Oli-neu cells. Luciferase activity was normalized to the cells transfected with the empty vector (* $p < 0.05$ unpaired two-tailed Students' t test). (e, f) Histograms showing the effect of the treatment with Cang or UDP-glc on the percentage of GPR17⁺, and β III-tub⁺ cells at the end of the neurogenic protocol #1 (e) or #2 (f). Data are the mean of 9-7 coverslips from 3 independent experiments. * $p < 0.05$ unpaired, two-tailed Student's t-test


Fig. 6

VPA expands the percentage of GPR17⁺ cells also expressing β III-tubulin in both neurogenic protocols. Representative pictures of cells grown according to neurogenic protocol #1 (a) or #2 (b) under the various experimental conditions. Arrows indicate “hybrid” GPR17/ β III-tub double positive cells. Scale bars: 100 μ m. (c) Histograms showing the percentage of GPR17/ β III-tub double-positive cells over the total number of GPR17⁺ cells at the end of neurogenic protocol #1. Results are the mean of 11-16 coverslips from 5-10 independent experiments. Neurogenic protocol #1: * $p < 0.05$ CTR vs Cang; ** $p < 0.01$ CTR vs VPA unpaired two-tailed Student's t-test. A non-significant trend to increase by VPA was observed in neurogenic protocol #2 (d). (e, f) The percentage of GPR17/ β III-tub double positive cells over the total number of β III-tub⁺ cells is not modified by the different pharmacological treatments.

In the case of neurogenic protocol #1, since the various drugs have been tested in separate experiments, the corresponding CTR values are reported for each pharmacological treatment (see panels c and e).


a


NEUROGENIC PROTOCOL #1







b







NEUROGENIC PROTOCOL #2














a**b****c**







Supplementary Fig. 1: Split fluorescence channels relative to picture in Figure 3D, showing that a typical bipolar β III-tubulin-positive cell (arrow; β III-tub, red in **a** and **c**) does not express NG2 (green in **b** and **c**). Scale bars: 100 μ m.